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Abstract Osteosarcoma (OSA) is the most common type of
bone tumors in dogs, which has high metastasis ability. 80 %
of dogs with OSA die due to lung metastasis. As a result its
treatment is a challenge for veterinary practitioners. The au-
thors discuss the etiology, pathogenesis and the possible risk
factors of OSA. The article focuses on literature review and
the study of recent advances in OSA treatment. The authors
describe therapies which have significantly prolonged the
lives of dogs, as well as those that have proven to be ineffec-
tive. Advantages and disadvantages of limb amputation and
limb-sparing surgery have been described. Authors present
also the results of both single agent’s therapies with the most
commonly used drugs as cisplatin, carboplatin and doxorubi-
cin and compare them to the results obtained using combined
chemotherapy. The use of nanotechnology as a new approach
in OSA treatment in order to avoid multidrug resistance and
reduce negative side effects of cytostatic drugs is presented.
The main reasons of the therapies failure are also provided in
this article.
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Introduction
Osteosarcoma (OSA) is the most common bone tumor in
dogs (more than 80 % of malignant bone tumors). It mainly
occurs in large and giant breeds such as: Rottweiler,
German Shepherd, Boxer, Doberman Pinscher, Irish Setter
(Spodnick et al. 1992; Berg 1996; Cavalcanti et al. 2004;
Morello et al. 2011). It most often appears in middle age
dogs (between 6 and 10 years old) (Thompson and Pool
2002; Morello et al. 2011), but it has also been reported in
1–2 year old dogs (Brodey 1979). The topographic location
is the appendicular skeleton (64 % of cases), the axial
skeleton (28, 5 %) (ribs and skull) (Fig. 1) and the
extraskeletal muscles (7, 5 %) (Calvacanti et al. 2004;
Trost et al. 2012). Appendicular OSA appears more often
in forelimbs than in hindlimbs, whereas extraskeletal OSA
develops primarily in visceral organs (adrenal gland, eye,
gastric ligament, ileum, kidney, liver, spleen, testicle and
vagina) (Langenbach et al. 1998).
Risk factors
The ethiopathogenesis of OSA is unknown, but various pre-
disposing factors (sex, body weight) may lead to its develop-
ment. Dogs with a body weight above 40 kg are more
predisposed than smaller dogs (Bergman et al. 1996). Most
of the studies indicate that this neoplasm tends to affect males
more often than females (Brodey and Abt 1976; Jongeward
1985; Pool 1990; Selverajah and Kirpenstein 2010). However,
according to certain reports also females are predisposed.
Cooley et al. (2002) indicate that there may be a correlation
between castration and a higher risk of tumor development.
Male and female dogs that underwent gonadectomy before
1 year of age had a one in four lifetime risk for bone sarcoma
and they were significantly more likely to develop bone
sarcoma than dogs that were sexually intact.
The location of a neoplasm increases the hazard of metas-
tasis and mortality. Tumors localized at distal radius are asso-
ciated with a lower hazard of metastasis, while tumors local-
ized at proximal humerus and distal femur or proximal tibia
have a high metastasis ability, which in turn results in a
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significant increase in mortality (Schmidt et al. 2013). Clinical
signs depend on the location of primary tumors. In appendic-
ular OSA, the typical clinical signs are: lameness (with or
without noticeable pain) and local swelling at the tumor site,
which is usually a consequence of the tumor’s extension into
the surrounding soft tissues (Brodey 1979; Jongeward 1985).
Diagnosis
Diagnosis is based on physical examination, radiography of
the lesion and fine needle biopsy performed in order to iden-
tify the type of tumor (Fig. 2) (Mehl et al. 2001; Thompson
and Pool 2002). X-Ray of the chest is recommended as an
additional test because of high metastatic risk. A blood test,
CT scan or MRI should be performed if limb-sparing surgery
is considered. According to the TNM system (T-tumor, N-
lymph node, M-metastasis) it is possible to differentiate 3
stages of the disease. Stage I includes low-grade (G1) lesion
without evidence of metastasis (M0); stage II includes high-
grade (G2) lesion without metastasis (M0); and stage III is
lesion with metastasis disease (M1). Irrespectively of the
histologic grade, the stages I and II are subdivided by the
anatomic setting for two groups (A, B). Group A is
intracompartmental (tumor has remained within the bone)
(T1), while group B is extracompartmental (tumor has extend-
ed beyond the bone into other nearby structures) (T2). Most
dogs are diagnosed with stage IIB OSA (Withrow et al. 2013).
Treatment
Treatment includes: surgery (limb amputation or limb-sparing
surgery), radiotherapy and chemotherapy (Boston et al. 2006).
Amputation is a first-line procedure, which increases survival,
brings pain relief, thereby delays euthanasia (Spodnick et al.
1992; Thompson and Pool 2002; Selvarajah and Kirpenstejin
2010). It completely removes the primary tumor, decreases the
risk of postoperative complications, shortens the time of an-
esthesia and decreases the expense in comparison with the
limb-sparing procedure (Jehn et al. 2007).
Surgical treatment
Surgery (either limb amputation or limb-sparing surgery) is
the first method of treatment. Limb-sparing surgery is an
alternative method to limb amputation. It is a surgical proce-
dure in which the bone tumor is resected without limb ampu-
tation by reconstructing the excised bone segment, thus pre-
serving the limb. Covey et al. (2014) insisted that internal
fixation when following stereotactic radiosurgery may be a
viable alternative to limb amputation. The bone can be recon-
structed with an endoprothesis (metal implant) or cortical
allograft. It has been proven that the type of implant has no
influence on the construct failure or on the postoperative
infection (Liptak et al. 2006). Circular external fixators are
also commonly used. Limb function is preserved in over 80 %
of dogs following limb-sparing surgery, however, complica-
tions such as infections (in 30–50 % of patients) or implant
failure (20–40 %) are relatively common. Moreover, tumor
recurrence appears in 15–25 % of cases. As a result this
technique is recommended for dogs with compromising neu-
rologic or orthopedic problems, or it can be favorable for
owners who refuse to perform limb amputation (Straw and
Withrow 1996; MacDonald and Schiller 2010).
Fig 1 A 10-year old mixed breed dog with skull osteosarcoma
Fig 2 Canine osteosarcoma stained with hematoxylin-eosin method,
original magnification 200x
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However, dogs treated with surgery alone have a short
median survival time. Authors from North Carolina State
University showed that 72, 5 % of dogs with appendicular
OSA treated by amputation alone died or were euthanized
because of metastases after 138 days (from diagnosis)
(Spodnick et al. 1992). As OSA are highly aggressive tumors,
micrometastasies occur in over 90 % of dogs. (O’Brien et al.
1993; MacEwen and Kurzman 1996; Selvarajah and
Kirpensteijn 2010). Usually metastases occur in the lungs
and bones, but they may be also found in regional lymph
nodes or internal organs (spleen, liver) (Ogilvie et al. 1993).
The information in medical records collected between 1986
and 2003 suggests that dogs with regional lymph nodes
metastasies live shorter (48 days) than dogs without
metastasies in lymph nodes (318 days) (Hillers et al. 2005).
Outcomes gathered during 19 years showed staging results.
Dogs with stage III OSA had poor prognosis. The median
survival time was 76 days (Boston et al. 2006).
Chemotherapy
As a result, various studies have been performed to assess if
the survival of dogs with OSA can be prolonged by adjuvant
therapy (Berg 1996; Moore et al. 2007; Phillips et al. 2009;
Skorupski et al. 2013). Latest reports show efficiency of a few
cytostatic drugs. Most commonly used cytostatics are:
carboplatin, cisplatin, and doxorubicin.
Carboplatin
Authors from Veterinary Specialty Hospital of San Diego
compared the median survival time of 48 dogs with appen-
dicular OSA after receiving single-agent carboplatin (300 mg/
m(2) IV q21d for 4 cycles) following amputation to amputa-
tion alone. Dogs treated with adjunctive therapy had a
prolonged median survival time (307 days) in comparison to
those after surgery alone (approximately 138 days) (Bergman
et al. 1996; Phillips et al. 2009). Saam et al. (Saam et al. 2011)
compared the outcomes collected between 1996 and 2006
from 65 dogs with adjuvant carboplatin-treated OSA using a
similar protocol and showed that carboplatin administration is
well tolerated and median survival time is similar to those
treated with other chemotherapeutics (doxorubicin or cisplat-
in). Interesting studies were performed by Simcock et al.
(Simcock et al. 2012) who evaluate the adverse effects and
survival times in 17 dogs that had OSA treated with a single
subcutaneous infusion of carboplatin (dosage 300 mg/m2
infused over a 3, 5 or 7 day period) as an adjunctive therapy
following the amputation of the affected limb. The results
were comparable to those of previous reports, where
carboplatin was given intravenously. However, it should be
noticed that there were only 17 dogs included in the study;
therefore further studies should be performed in order to
confirm these results.
Cisplatin
Some authors indicate a significantly longer median survival
time for dogs with appendicular OSA treated with cisplatin as
an adjuvant therapy to amputation or limb-sparing surgery
(322 days), than with surgery alone (138 days) (Kraegel
et al. 1991; Berg et al. 1992). Similar results were published
by Straw et al. (Straw et al. 1991), who showed that 71 dogs
treated with cisplatin as an adjuvant therapy had significantly
longer median survival times than dogs with no chemothera-
py. However, in the treated group 73, 4 % of dogs were
euthanatized because of the problem related to metastases,
which was significantly higher than in the group of dogs with
amputation alone. The results obtained indicate that cisplatin
treatment is effective, but it does not inhibit metastases.
Another research of Hahn et al. (1996) assessed the effective-
ness of cisplatin administrated intramedullary. The survey
concerned 4 dogs with OSA to such an advanced stage that
they were not eligible for an amputation or limb-sparing
surgery. One out of four dogs undertaken with this treatment
was found to be tumor-free, another one had partial remission
of local neoplasm and in two dogs the disease had evolved.
However, there were only 4 dogs included in the study, which
weakens the reliability of the results. Further studies including
many more animals should be performed.
Doxorubicin
It is believed that doxorubicin used in OSA treatment is as
effective as cisplatin or carboplatin. One of the first researches
on doxorubicin’s effectiveness was conducted in 1995. Berg
and associates (1995) compared the results of 35 dogs with
appendicular OSA treated with 5 doses of doxorubicin
(30 mg/m2 of body surface, i.v., every 2 weeks) and limb
amputation (after second or third dose) with a historical con-
trol group of 162 dogs who were treated with amputation
alone. The median survival time for dogs receiving adjunctive
therapy was 366 days, which was significantly longer than for
the control group (138 days). Similar results were presented
byMoore et al. (Moore et al. 2007), whose study included 303
dogs with appendicular OSA. The way of doxorubicin admin-
istration was similar to the one in the previous report.
Doxorubicin demonstrated efficacy in the slowing of metas-
tasis in dogs with appendicular OSAwith a 1-, 2-, and 3-year
median survival time of 35, 17, and 9 % respectively (Moore
et al. 2007). The results obtained are similar to those with
carboplatin as the adjunctive method of treatment, which
indicates that both drugs may be used to prolong patients’
lives, however, neither of them inhibits metastasis.
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Alternative treatment
Alternative chemotherapy protocols include using lobaplatin
or ifosfamide. Salvage treatment with ifosfamide was evalu-
ated in the group of 19 dogs with OSA and previously treated
with standard chemotherapy. Median ifosfamide dosage was
375 mg/m2 administered on average 2 times. The finding
indicated that ifosfamide was well tolerated but has minor
anti-tumor activity (Batschinski et al. 2012). Promising results
were described by Kirpensteijn et al. (2002), who examined
the efficiency of lobaplatin on the group of 28 dogs with OSA.
Dogs were treated with surgical resection of undertaken limb
and adjuvant lobaplatin chemotherapy at a dose of 35 mg/m2
i.v. once every 3 weeks, for a maximum of 4 doses. Compared
to historic controls treated with surgery alone, the results
suggest that lobaplatin prolonged the disease free interval
and survival time in dogs with OSA. More than 20 %
of dogs achieved a 1 year disease free interval and
more than 30 % of dogs reached a 1 year survival time
(Kirpensteijn et al. 2002).
Combined chemotherapy
Another attempt to improve chemotherapy’s effectiveness was
to compare the effects of two cytostatic drugs given in an
alternating schedule. The efficiency of alternating the admin-
istration of cisplatin and doxorubicin after amputation was
evaluated. 38 dogs treated with combined therapy after am-
putation had a significantly longer survival time than dogs that
were treated with amputation alone, yet the result was still
similar to the one achieved during monotherapy which in-
volves carboplatin or doxorubicin (Mauldin et al. 1988; Chun
et al. 2000). Moreover, the results of subsequent studies
confirm that a disease-free interval and survival time are close
to those reported for single-agent protocols (Kent et al. 2004;
Bacon et al. 2008). Similar conclusions were presented by
Selmic et al. (Selmic et al. 2014), who performed a retrospec-
tive cohort study which included 470 dogs with appendicular
OSA. They compare their median survival time and adverse
effects after therapy with surgery and carboplatin, doxorubicin
or both of them (using 5 different protocols). The results
achieved demonstrate that combining the two drugs does not
increase the median survival time in comparison to monother-
apy. However, lower adverse effects were observed in those
patients. On the other hand, Lane et al. (2012) and Skorupski
et al. (2013) indicate that dogs with appendicular OSA receiv-
ing carboplatin alone had significantly longer disease-free
intervals than dogs receiving carboplatin and doxorubicin in
an alternating schedule. To sum up, there is no clear evidence
if combined chemotherapy is more efficient than single agent
therapy, however, it may reduce negative side effects, which
might indicate that using multiple drugs in a long lasting
therapy increases the quality of patients’ lives.
Experimental treatment
In order to increase efficacy of OSA treatment and reduce the
metastasis ability scientists performed many studies in which
they modified standard chemotherapy treatment by adding
different substances, such as: pamidronate (a nitrogen contain-
ing bisphosphonate, antiosteoporosis drug, which was found to
show high cytotoxicity against osteosarcoma cell lines),
gemcitabine (nucleoside analog used as chemotherapeutic
agent), BAY 12–9566 (a matrix metalloproteinase inhibitor that
shows a possibility to inhibit metastasis ability of tumor cells),
suramin (a polysulfonated naphylurea which in vitro increases
the tumor’s sensitivity to chemotherapeutic agents) or
liposome-encapsulated muramyl tripeptide (which has been
shown to regress spontaneous metastasis by activating macro-
phages). Unfortunately, the results showed that the addition of
pamidronate to carboplatin chemotherapy for treatment of ca-
nine OSA, despite being safe, does not impact the efficacy of
standard treatment (Kozicki et al. 2013). Also the results
achieved by enriching carboplatin monotherapy with
gemcitabine were comparable to those reported for carboplatin
alone, which did not improve the outcome (McMahon et al.
2011). Another study was performed on 303 dogs to check
whether adding BAY 12–9566 can improve OSA treatment
based on doxorubicin followed by limb amputation. Treatment
with BAY 12–9566 did not influence the survival time. The
median survival time in both groups was less than 8 months
(Moore et al. 2007). Authors evaluated the combination of
noncytotoxic suramin and doxorubicin after amputation in dogs
with OSA. In conclusion of this experiment similar results to
monotherapy median disease free time was achieved (Alvarez
et al. 2014). Also Kurzman and associates (1995) showed that
benefits of adding Liposome-encapsulated Muramyl
Tripeptyde to standard chemotherapy treatment (with cisplatin)
and surgery is time. They showed that there is no survival
advantage of administering Liposome-encapsulated Muramyl
Tripeptyde concurrently with cisplatin chemotherapy and sur-
gery, while the addition of Liposome-encapsulated Muramyl
Tripeptide following cisplatin treatment significantly increased
the median survival time (14,4 months) as opposed to other
groups - treated with surgery, cisplatin and liposomes alone
(9,8 months). This dogs had also a significantly longer
metastasis-free interval (p<0.035) compared to dogs given
placebo liposomes. The results obtained by Kurzman
et al. (1995) show that Liposome-encapsulated Muramyl
Tripeptide has significant antitumor activity when administered
alone, but this effect is not observed when giving concurrently
with chemotherapeutic agent as cisplatin.
New therapeutic approach to overcome multidrug resistance
One of the most important cause of ineffective chemotherapy
treatment of OSA is due tomultidrug resistance (MDR).MDR
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in cancers is frequently associated with the overexpression
and higher activity of efflux pumps (mainly p glycoprotein –
PGP) that prevents intracellular accumulation of the drugs in
cancer cells resulting in obtaining too low concentration of the
drug inside the cell. PGP is a gene product of multidrug
resistance protein 1 gene (MDR1). As a result silencing
MDR1 mRNA expression is a new approach for overcoming
MDR. On the other hand, some nanoparticles due to their
nanoscopic size (lower than 100 × 10−9 m) have the ability to
bypass MDR entering the neoplastic cells through endocyto-
sis. Susa et al. (Susa et al. 2010) in a pilot in vitro studies
showed that both doxorubicin and siRNA encapsulated in
liposome-based dextran nanoparticles cause the simultaneous
suppression of drug efflux pumps and have higher cytotoxic
effect both on drug sensitive and drug resistance OSA cells.
Kimura et al. (2013) and Sha et al. (Sha et al. 2013) presented
in vitro studies with fucoidan nanoparticles and dioxide nano-
particles on human osteosarcoma cell lines, which suggest that
they may be a potent new therapeutic agents to treat primary
tumors as well as to minimize or prevent the reccurence of
OSA. However, in vivo studies should be performed to con-
firm such hypothesis.
Until now, in veterinary medicine only a few studies in-
cluding nanoparticles for OSA treatment have been per-
formed, e.g. including the use of STEALTH liposome-
encapsulated cisplatin. STEALTH liposomes as nanocarriers
should slowly release the antracyclin drug in the acidic envi-
ronment of the neoplastic tissue and should enable to reach
higher concentration of the drug in tumor tissue according to
retention and permeability effect. As a result, Vail et al. (Vail
et al. 2002) compared STEALTH liposome-encapsulated cis-
platin therapy (SPI-77) with standard carboplatin therapy in
dogs with OSA. Dogs were treated with SPI-77 in 350 mg/m2
dosage i.v. 3-times every 3 weeks. Carboplatin was given in
standard therapy (300 mg/m2 i.v. every week for 4 treat-
ments). However, the results obtained were unsatisfactory as
dogs treated with carboplatin alone achieved similar disease
free-survival and overall survival compared to dogs treated
with SPI-77 (disease free survival time was 156 and 123 days,
respectively (p=0.19). (Vail et al. 2002).
Radiotherapy
Radiation therapy is considered to be a palliative method of
treatment. The intent is to provide pain relief and prolong
patients’ lives. However, it is not easily accessible and re-
quires a general anesthesia of the patient. Studies performed
by Oblak et al. (Oblak et al. 2012) proved that combined
therapy including surgery, chemotherapy and radiotherapy is
nowadays the most effective way of treatment. Fifty dogs
were included in the study and median survival times between
those that received palliative radiation therapy alone, and in
combination with chemotherapy, pamidronate, or both were
compared. Median survival times were the longest for dogs
receiving radiotherapy together with chemotherapy
(307 days) and the shortest in dogs receiving radiotherapy
and pamidronate (69 days). Chemotherapy in addition to
radiotherapy gave satisfying results, while enriching radio-
therapy with pamidronate was ineffective (Oblak et al. 2012).
Conclusions
Canine osteosarcoma is a highly malignant bone tumor in
dogs with a high metastasis ability. Nowadays, combining
surgery with single agent chemotherapy and radiotherapy
seems to be the most effective method of OSA treatment.
However, reducing the high metastasis ability and enhancing
antitumor activity of cytostatic drugs having minimal negative
side effects is still a challenge for veterinary practitioners.
New approaches of OSA treatment including the use of nano-
particles are currently under investigation. The results of
in vitro studies with fucoidan nanoparticles or dioxide nano-
particles on human osteosarcoma cell lines suggest that they
may be a potent new therapeutic agents to treat primary
tumors as well as to minimize or prevent the recurrence of
OSA . Doxorubicin and siRNA encapsulated in liposome-
based dextran nanoparticle could potentially be utilized to
develop novel therapies. Many such therapies used in human
medicine aimed at stopping metastatic disease could be help-
ful in dogs with OSA, however, further in vitro and in vivo
studies in veterinary medicine are needed.
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